Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First-Line Japan Alecensa Trial Stopped Early On Benefits

This article was originally published in Scrip

Executive Summary

A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding well for the ALK inhibitor in this important setting.


Related Content

Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC
Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts